Aethlon Medical (NASDAQ:AEMD) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reduced their price target on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating for the company in a research report on Monday, June 24th.

Aethlon Medical Price Performance

AEMD stock opened at $0.43 on Friday. Aethlon Medical has a 12 month low of $0.24 and a 12 month high of $2.35. The firm has a market cap of $5.99 million, a PE ratio of -0.09 and a beta of 1.72. The firm has a 50 day simple moving average of $0.39 and a 200 day simple moving average of $0.75.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.10. During the same quarter in the previous year, the company posted ($1.30) earnings per share. As a group, sell-side analysts expect that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.